30 . 06 .2022
Press release
Galderma and Children’s Skin Disease Foundation Celebrate Decade-Long Partnership
22 . 06 .2022
Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)
08 . 06 .2022
Press release
Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium
02 . 06 .2022
Press release
Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
01 . 06 .2022
News story
Actinic Keratosis prevention campaign encourages everyone to ‘FACE THE FACTS’
31 . 05 .2022
Press release
Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022
25 . 04 .2022
Press release
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
04 . 04 .2022
Press release
Galderma launches a virtual experience this Rosacea Awareness Month showcasing how the condition goes beyond the visible with Rosacea Space